Assessment of risk for pre-eclampsia at mid-gestation to define subsequent care.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 40248972.
- Also identified by DOI 10.1002/uog.29222 and PMC identifier 12127725.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
To stratify pregnancy care based on the estimated risk of pre-eclampsia (PE) from screening at 19-24 weeks' gestation by combinations of maternal risk factors, estimated fetal weight (EFW), mean arterial pressure (MAP) and uterine artery pulsatility index (UtA-PI). The data for this study were derived from a prospective non-interventional study in 134 443 women with a singleton pregnancy attending for a routine ultrasound scan at 19 + 0 to 23 + 6 weeks' gestation in two UK maternity hospitals. The visit included recording of maternal demographic characteristics and medical history, sonographic EFW and measurement of MAP and UtA-PI. The competing-risks model was used to estimate the individual patient-specific risk of delivery with PE at < 28, < 32 and < 36 weeks' gestation. Receiver-operating-characteristics curves were constructed for screen-positive rates (SPRs) at different detection rates of delivery with PE at < 28, < 32 and < 36 weeks' gestation for the combinations of maternal risk factors, EFW and MAP, and of maternal risk factors, EFW, MAP and UtA-PI. Different risk cut-offs were used with the intention of detecting about 80%, 85% and 90% of cases of delivery with PE at < 28, < 32 and < 36 weeks' gestation. Calibration for risk of delivery with PE at < 28, < 32 and < 36 weeks' gestation was assessed by plotting the observed incidence of PE against the predicted incidence of PE. The study population contained 4335 (3.2%) women that subsequently developed PE, including 64 (0.05%) that delivered with PE at < 28 weeks' gestation, 209 (0.2%) that delivered with PE at < 32 weeks and 655 (0.5%) that delivered with PE at < 36 weeks. If the objective of screening was to identify about 90% of cases of delivery with PE at < 28, < 32 and < 36 weeks and the method of screening was a combination of maternal risk factors, EFW and MAP, the respective SPRs would be 11.0%, 18.3% and 38.8%. If the method of screening also included UtA-PI, the respective SPRs would be 2.6%, 3.8% and 23.6%. If the objective of screening was to identify about 80% of cases of delivery with PE at < 28, < 32 and < 36 weeks and the method of screening was a combination of maternal risk factors, EFW and MAP, the respective SPRs would be 5.9%, 9.7% and 21.9%. If the method of screening also included UtA-PI, the respective SPRs would be 1.0%, 2.1% and 11.7%. The calibration plots demonstrated good agreement between the estimated risk and observed incidence of PE. All women should be offered assessment of risk for PE at 11-13 weeks, to help identify those requiring aspirin prophylaxis to reduce the rate of preterm PE, and at 35-37 weeks, to determine the optimal timing of birth to reduce the rate of term PE. Assessment of risk for PE at mid-gestation can be used to identify the subgroups that require additional monitoring at 24-35, 28-35 and 32-35 weeks' gestation. The best performance of screening, reflected in the SPR necessary to achieve a high detection rate, is achieved by a combination of maternal risk factors, MAP and UtA-PI. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Medical subject headings
- Pre-Eclampsia
- Uterine Artery
- Ultrasonography, Prenatal